To this day, the cell-based secreted gp96-Ig vaccine approach was tested and completed in a Phase 1b/2 study of Viagenpumatucel-L (HS-110) in combination with multiple treatment regimens in patients with non-small cell lung cancer (NSCLC) (The “DURGA” Trial)(NCT02439450) [71,78]. This evidence concerns the gene HSP90B1 and non-small cell lung carcinoma.